May 4, 2023 by Jason Wertheimer Sonoma Bio Co-Founder and Chief Executive Officer Jeffrey Bluestone, Ph.D., Elected to the National Academy of Sciences Read More
April 11, 2023 by Jason Wertheimer Sonoma Biotherapeutics Appoints Leaders in Cell Therapy and Immunology to Scientific Advisory Board Read More
March 28, 2023 by Jason Wertheimer Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases Read More
November 10, 2022 by Jason Wertheimer Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2022 Read More
September 7, 2022 by Jason Wertheimer Sonoma Biotherapeutics Appoints Jessica Stitt as Chief Financial Officer Read More
August 24, 2022 by Jason Wertheimer Sonoma Biotherapeutics Enters Long-Term Lease Agreement to Establish a Treg Cell Therapy R&D and Manufacturing Center Read More
August 17, 2022 by Jason Wertheimer Sonoma Biotherapeutics Expands Board of Directors with Appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPH Read More
June 8, 2022 by Jason Wertheimer Sonoma Biotherapeutics Announces FDA Clearance of Investigational New Drug Application for SBT115301, an Effector T Cell-Modulating Biologic for Autoimmune Diseases Read More
November 16, 2021 by Jason Wertheimer Sonoma Biotherapeutics Appoints Heidi Hagen, MBA as Chief Technical Officer Read More
September 16, 2021 by Jason Wertheimer Sonoma Biotherapeutics Expands Leadership Team with the Appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary Read More